FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on Pressure BioSciences Names the Vogel Laboratory at New York University’s Center for Genomics and Systems Biology a Center of Excellence”
Pressure BioSciences, Inc. (OTCQB: PBIO) announced the establishment of a Center of Excellence at Dr. Christine Vogel’s laboratory at New York University’s Center for Genomics and Systems Biology.
Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.
Diseases are commonplace around the world, especially in regions that don’t have access to adequate healthcare. In such underdeveloped regions, diseases such as AIDS, malaria, and tuberculosis ravage countries and their inhabitants. According to the World Health Organization, in third world countries, people face tens of thousands of deaths daily due to untreated conditions and many of these diseases occur through environmental impacts or purely through hereditary conditions. However, even in developed countries, cases of cancer, heart disease, respiratory disease, and diabetes are growing. The alarming rates have also prompted biotechnology companies to conduct research and development of new treatments in order to effectively combat the growing incidences. According to data compiled by Polaris Market Research, the global biotechnology market was valued at USD 390.1 Billion in 2017 and is projected to reach USD 741.7 Billion by 2026. Furthermore, the market is expected to witness a CAGR of 7.7% during the forecast period from 2019 to 2026. Specifically, the market is expected to be propelled by the growing number of R&D expenditures and the outsourcing activities by both private and government bodies. Moreover, the rising number of future conferences and workshops is also expected to bolster the industry’s growth.
In 2017, biopharmacy applications accounted for approximately 60% of the overall biotechnology market share. The sector itself is expected to continually flourish due to the increased use of bio-recombinant proteins in many of the medications used to treat ailments, as biopharma companies are now focusing on improving customized medicine to further enhance patient recovery. The major difference between biopharmaceutical and pharmaceutical companies is that the former focus on a compound of chemical synthesis which is developed in academic and industrial laboratories, according to Morgan Mckinley. These companies are much more focused on research in order to develop effective treatments. Overall, the growing number of life-threatening medical conditions will further accelerate the overall biotechnology industry’s growth. “Biotechnology is a huge part of our everyday lives, from the clothes we wear, the food we eat, the medicine we use to keep us healthy and even the fuel we use to take us around. Biotech already plays, and will continue to play, an invaluable role in meeting our needs. No other industry is better placed to enhance quality of life and respond to society’s ‘Grand Challenges’ of tackling an ageing and ever-increasing population, healthcare and affordability, resource efficiency, food security, climate change and energy shortages,” said Jason Johal, Manager at CK Sciences.
For more information, please visit: Pressure Biosciences, Inc.
For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.